Side effects and complications in the use of drugs: asymptomatic hypotension, symptomatic hypotension (diaphoresis, dizziness), violations of peripheral blood circulation, pallor, flush to the face, bradycardia (heart rate below 50 beats / min) chest pain, syncope, pulmonary edema and AV-block, bradycardia / sinus pause promoted asystole, dizziness, drowsiness, confusion, headache, psychomotor agitation, feelings of fatigue, paresthesia, asthenia, depression, violation thinking, anxiety, anorexia, convulsions, respiratory - bronchospasm, difficulty breathing, shortness of breath, nasal hyperemia, wheezing, gastrointestinal tract - nausea, vomiting, dyspepsia, constipation, dry mouth and discomfort in the abdomen, breach of taste feelings; adverse reactions at the injection site, including inflammation and consolidation, swelling, redness or color change skin burning sensation at the injection site, thrombophlebitis and local skin necrosis with extravasation, urinary retention, speech disorders, vision, pain in the area mizhlopatkovyy, chills and Loss of Resistance To Air in perioperative period - bradycardia and bronchospasm. Indications for use drugs: treatment SUPRAVENTRICULAR tachycardias such as AV-nodal tachycardia, supraventykulyarna tachycardia in patients promoted WPW c-IOM and paroxysmal form of atrial fibrillation, ventricular tahiarytimiyi severe. Method of production of drugs: Table., Coated tablets, 150 mg, 300 mg. Contraindications to the use of drugs: pronounced bradycardia (HR less than 50); SSSV; AV-block and CA-II - III degree, cardiogenic shock; g CH, hypersensitivity to the drug, age 18 years (safety and efficacy of the drug not established). states. Contraindications to the use of drugs: hypersensitivity to Retinal Detachment drug; AV block II - III degree, cardiogenic promoted expressed hypotension, severe heart failure, sinus weakness, liver and kidney disease, pregnancy, lactation, infancy. Dosing and Administration of drugs: SUPRAVENTRICULAR tahiarytmiya - dosage should be chosen individually by titration in which each step contains a loading dose and subsequent dose supportive, always loading dose of 500 mg / kg (0.05 ml / kg at concentrations of 10 mg / ml), which here introduced for 1 min, supporting effective dose drug for the treatment SUPRAVENTRICULAR tahiarytmiyi is 50-200 mg / kg / min, although used and such high doses, 300 mg / kg / min.; for a small number of patients sufficient dose is 25 mg / kg / min; scheme beginning of treatment and maintenance therapy - Loading dose of 500 mg / kg / min for 1 min, then maintenance dose 50 mg Alkaline Phosphatase kg / min for 4 min, with a positive result - maintenance dose 50 mg / kg / min., with negative results within 5 minutes - repeat administration with dosages of 500 mg / kg / min for 1 min to improve the supportive dosage to 100 mg / kg / min for 4 min, a positive result - maintenance dose of 100 ug / promoted / min., with negative results within 5 minutes - repeat administration with dosages of 500 mg / kg / min for 1 min; sustaining dose increase to 150 mg / kg / min for 4 min, a positive result: the introduction of a maintenance dose of 150 mg / kg / min., with negative results - repeat administration with dosages of 500 mg / kg / min for 1 min to improve the supportive dose to 200 mg / kg / min and keep at that level, while achieving the desired degree of reduction in heart Hematocrit or ceiling security to stop the introduction of loading dose and dosing interval to reduce the base maintenance of the promoted of the 50 mg / kg / min to 25 mg / kg / min or promoted lower, if necessary, the interval between titration steps can be increased from 5 to 10 minutes, with emergence of adverse events can reduce dose or stop the introduction, pharmacological adverse reactions should stopped for 30 minutes. Method of production of drugs: Mr injection, 10 mg / ml to 10 ml vial. The main effect of pharmaco-therapeutic effects of drugs: antianginal, antihypertensive, antiarrhythmic action; cardioselective ?1-adrenoceptor blocker with rapid onset and a very small duration, in therapeutic doses has no sympatomimetychnoyi and membranstabilizuyuchoyi activity, reduces catecholamines stimulated cAMP formation from ATP, reduces intracellular Ca2 + flow, reduces heart rate, slows conduction, reduces skorotnist infarction effect of the drug starts with Since the introduction, the maximum therapeutic effect develops in 2 minutes after administration and ending 10-20 min after cessation of infusion, has enzymatic labile essential link. Dosing and Administration of drugs: the recommended dose for adults - the therapeutic dose for patients weighing 70 kg, as typically is 450 - 600 mg / day (150 mg 3 g / day or 300 mg, 2 g / day) in some cases may require increase daily dose to 900 mg (300 mg 3 g / day) - MDD, patients with lower body weight to reduce the dose; increase the recommended dose gradually, at intervals of 3-4 days, the duration of treatment is determined by the clinical condition of the patient.
Nenhum comentário:
Postar um comentário